Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma

NCT04609293 | Unknown

• 1 other identifier: 20200903
• Study Type: observational
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

This trial will explore effectiveness and safety using the combination therapy of camrelizumab，apatinib and hyperfractionated radiotherapy in patients with renal cell carcinoma(RCC). Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.immunotherapy. hyperfractionated radiotherapy, represented by stereotactic body radiation therapy (SBRT), can significantly improve the radiotherapy sensitivity of RCC. This trial will also observe whether SBRT can bring about immune effects and explore the group and individual indicators that affect the treatment effect of RCC.

Conditions

Renal Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Objective response rate（ORR）

  Objective response rate, which is defined as the proportion of subjects who achieve a best response of complete response (CR) or partial response (PR) using the RECIST 1.1 criteria.

  3 years

Secondary Outcomes (8)

• Subject safety

  Date of signing of informed consent form until 12 weeks after the last medication

• Progression free survival (PFS)

  3 years

• Disease control rate(DCR)

  3 years

• Overall Survival(OS)

  3 years

• Local Control Rate

  3 years

Study Arms (1)

Camrelizumab+apatinib+Hypofractionated radiation therapy

Camrelizumab:200mg every 2 weeks for 1 years or until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment. Apatinib:250mg everyday until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment. Radiation: one week following completion of the second immunotherapy, hypofractionated radiotherapy with marginal dose of 50Gy/2Gy/25f and tumor center dose of local hyperfraction increase 24-32Gy/8-12Gy/3-4f will be performed 3-5 times. The routine radiotherapy will be started at the same time as the third immunotherapy and 25 times routine radiotherapy will be completed before the fifth or sixth immunotherapy.

Combination Product: camrelizumab+apatinib+hyperfractionated radiotherapy

Interventions

camrelizumab+apatinib+hyperfractionated radiotherapy COMBINATION_PRODUCT

Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy

Camrelizumab+apatinib+Hypofractionated radiation therapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Continuous sampling was performed in the Department of Radiotherapy, Peking University First Hospital.

You may qualify if:

• Patients with clear cell renal cell carcinoma were confirmed by histological or cytological;
• Locally advanced/metastatic (the newly diagnosed stage IV RCC assessed by AJCC) or recurrent RCC;
• Have not received or received systemic treatment for first-line advanced HCC (including but not limited to a variety of targeted therapies including TKI, VEGF and mTOR);
• The number of measurable lesion is not more than 5, or although the number of measurable lesion is more than 5, but the radiotherapy department and imaging doctors evaluate that the measurable lesions that can accept radiotherapy are more than or equal to 3;
• According to RECIST 1.1 standard, there will be clinically assessable lesions, and the target lesion has not received radiotherapy before;
• Male or female,from 18 to 75 years;
• The life expectancy will be longer than 6 months;
• ECOG score will be 0 - 2;
• The main organ functions are normal, and there is no serious blood, heart, lung, liver, kidney dysfunction and immune deficiency diseases. The results of laboratory test must be met the following criteria: Neutrophils: more than 1.5 × 109/L; ; Platelets: more than 100 × 109/L; Hemoglobin: more than 100g/L; serum albumin：more than 30 g/L; bilirubin：less than the upper normal limit (ULN); ALT and AST：less than 2.5 folds of the upper normal limit (ULN)，if there is liver metastasis, ALT and AST must be less than 5 folds of the upper normal limit (ULN) ; Serum Creatinine: less than 1.5×ULN; Blood Urea Nitrogen (BUN): less than 2.5×ULN; Thyroid Stimulating Hormone (TSH): ess than the upper normal limit (ULN)，if abnormal, the T3 and T4 levels should be examined, and the T3 and T4 levels are normal;
• Be willing to comply with research and follow-up procedures;
• Female and male subjects should take effective contraceptive measures from the beginning of treatment to within 6 months after the end of treatment.Agreeing to participate in this study and signing a written informed consent.

You may not qualify if:

• Central nervous system metastasis (including brain metastasis, meningeal metastasis, etc.);
• Other immunosuppressive drugs used within 14 days before before study drug administration, excluding nasal sprays and inhaled corticosteroids or physiological doses of systemic steroids (ie not more than 10 mg/day of prednisolone or Other corticosteroids of equivalent pharmacological physiological dose);
• Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents: systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥ 90 mmHg;
• Clinically significant cardiovascular diseases：Myocardial ischemia or myocardial infarction above grade II, ventricular arrhythmia which poorly controlled，QTc\>450ms（male）/QTc\>470ms (female)；Congestive heart failure (New York heart association (NYHA) class is Ⅲ～Ⅳ)；or cardiac color Doppler ultrasound examination revealed that the left ventricular ejection fraction (LVEF) \<50%;
• Accompanied by uncontrolled pleural effusion, pericardial effusion, or ascites that requires repeated drainage;
• Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism;
• Asthma that requires intermittent use of bronchodilators or other medical intervention should be excluded（Asthma has been completely relieved in childhood, and those without any intervention after adulthood can be included）;
• Coagulation abnormalities (INR\>1.5、PT\>ULN+4s、APTT \>1.5 ULN）, with bleeding tendency or are receiving thrombolytic or anticoagulant therapy;
• Proteinuria ≥ (++) and 24 hours total urine protein \> 1.0 g;
• Received major surgery or suffered severe traumatic injury, fracture or ulcer within 4 weeks before enrollment;
• Severe infections (such as intravenous infusion of antibiotics, antifungal or antiviral drugs) within 4 weeks before the first administration, or unexplained fever\> 38.5°C during the screening period/before the first administration;
• Clinically significant hemoptysis or more than half a teaspoon (2.5ml) of hemoptysis per day occurred within 2 months before enrollment; or Clinically significant bleeding symptoms or tendency, such as gastrointestinal bleeding, hemorrhagic Gastric ulcer, fecal occult blood≥++ at baseline, or vasculitis, etc.;
• Arterial/venous thrombosis events occurred in the 12 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
• History of immunodeficiency or human immunodeficiency virus (HIV) infection: HBV DNA\>500 IU/ml, HCV RNA\>1000copies/ml, HBsAg+ and anti-HCV+；
• Has a known additional malignancy within the last 5 years, exceptions include basal cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer;

Sponsors & Collaborators

• Peking University First Hospital: lead

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases

Study Officials

• Xianshu Gao, MD,PhD

  Peking University First Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mingwei Ma, MD

CONTACT

15810160120; 15810160120@163.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: October 26, 2020
• First Posted: October 30, 2020
• Study Start: October 20, 2020
• Primary Completion: September 7, 2023
• Study Completion: May 7, 2024
• Last Updated: October 30, 2020

Record last verified: 2020-10

Data Sharing

• IPD Sharing: Will not share